Recap: Baudax Bio Q1 Earnings

 

Shares of Baudax Bio BXRX remained unaffected after the company reported Q1 results.

Quarterly Results

Earnings per share rose 93.30% over the past year to ($0.27), which missed the estimate of ($0.19).

Revenue of $198,000 higher by 0.00% year over year, which missed the estimate of $630,000.

Looking Ahead

Baudax Bio hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 05, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/9wuep9u4

Price Action

52-week high: $4.95

Company's 52-week low was at $0.97

Price action over last quarter: down 37.50%

Company Description

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs, and a related proprietary chemical reversal agent and Dex-IN.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!